Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 158.03 Thousand USD | 100.52% |
| 2022 | -30.27 Million USD | -22.36% |
| 2021 | -24.74 Million USD | -188.44% |
| 2020 | -8.57 Million USD | 22.97% |
| 2019 | -11.13 Million USD | -43.38% |
| 2018 | -7.76 Million USD | -46.41% |
| 2017 | -5.3 Million USD | 7.71% |
| 2016 | -5.74 Million USD | 34.98% |
| 2015 | -8.84 Million USD | -569.55% |
| 2014 | -1.32 Million USD | -6.26% |
| 2013 | -1.24 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.93 Million USD | 317.5% |
| 2024 Q1 | -4.74 Million USD | -1217.62% |
| 2023 Q3 | 372.63 Thousand USD | 131.78% |
| 2023 FY | 158.03 Thousand USD | 100.52% |
| 2023 Q1 | 2.53 Million USD | 110.43% |
| 2023 Q2 | -1.17 Million USD | -146.34% |
| 2023 Q4 | 424.72 Thousand USD | 13.98% |
| 2022 Q2 | -1.7 Million USD | 35.56% |
| 2022 Q1 | -2.64 Million USD | 81.81% |
| 2022 FY | -30.27 Million USD | -22.36% |
| 2022 Q4 | -24.24 Million USD | -1329.62% |
| 2022 Q3 | -1.69 Million USD | 0.34% |
| 2021 FY | -24.74 Million USD | -188.44% |
| 2021 Q2 | -4.54 Million USD | -70.08% |
| 2021 Q1 | -2.66 Million USD | 20.88% |
| 2021 Q3 | -3.01 Million USD | 33.6% |
| 2021 Q4 | -14.52 Million USD | -381.63% |
| 2020 Q1 | -2.34 Million USD | 42.13% |
| 2020 Q3 | -2.14 Million USD | -203.11% |
| 2020 Q4 | -3.37 Million USD | -57.41% |
| 2020 FY | -8.57 Million USD | 22.97% |
| 2020 Q2 | -707.16 Thousand USD | 69.87% |
| 2019 Q2 | -3.04 Million USD | -120.08% |
| 2019 Q3 | -2.38 Million USD | 21.75% |
| 2019 Q4 | -4.05 Million USD | -70.03% |
| 2019 FY | -11.13 Million USD | -43.38% |
| 2019 Q1 | -1.38 Million USD | 6.17% |
| 2018 Q4 | -1.47 Million USD | 31.28% |
| 2018 Q3 | -2.14 Million USD | -18.68% |
| 2018 Q2 | -1.81 Million USD | 22.43% |
| 2018 Q1 | -2.33 Million USD | -6.25% |
| 2018 FY | -7.76 Million USD | -46.41% |
| 2017 FY | -5.3 Million USD | 7.71% |
| 2017 Q4 | -2.19 Million USD | -38.61% |
| 2017 Q3 | -1.58 Million USD | -85.16% |
| 2017 Q2 | -855.66 Thousand USD | -27.9% |
| 2017 Q1 | -669.01 Thousand USD | 71.01% |
| 2016 Q1 | -949.2 Thousand USD | 21.08% |
| 2016 FY | -5.74 Million USD | 34.98% |
| 2016 Q4 | -2.3 Million USD | -102.23% |
| 2016 Q3 | -1.14 Million USD | 15.52% |
| 2016 Q2 | -1.35 Million USD | -42.29% |
| 2015 FY | -8.84 Million USD | -569.55% |
| 2015 Q3 | -2.54 Million USD | 0.12% |
| 2015 Q2 | -2.54 Million USD | 0.0% |
| 2015 Q1 | -2.54 Million USD | -629.92% |
| 2015 Q4 | -1.2 Million USD | 52.72% |
| 2014 Q4 | -348.96 Thousand USD | 0.0% |
| 2014 FY | -1.32 Million USD | -6.26% |
| 2013 FY | -1.24 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 99.672% |
| Embecta Corp. | 70.4 Million USD | 99.776% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 99.158% |
| Dynavax Technologies Corporation | -6.38 Million USD | 102.474% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 100.076% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 99.623% |
| PainReform Ltd. | -9.34 Million USD | 101.691% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 102.008% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 103.507% |
| SCYNEXIS, Inc. | 67.04 Million USD | 99.764% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 105.1% |
| Cosmos Health Inc. | -18.54 Million USD | 100.852% |
| Journey Medical Corporation | -3.85 Million USD | 104.102% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 103.507% |
| Safety Shot Inc | -15.08 Million USD | 101.048% |
| Alpha Teknova, Inc. | -36.78 Million USD | 100.43% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 100.113% |
| Bright Green Corporation | -13.12 Million USD | 101.204% |
| Procaps Group, S.A. | 42.54 Million USD | 99.629% |
| Theratechnologies Inc. | -23.95 Million USD | 100.66% |
| Harrow Health, Inc. | -24.41 Million USD | 100.647% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 103.269% |
| Biofrontera Inc. | -20.13 Million USD | 100.785% |
| DURECT Corporation | -27.62 Million USD | 100.572% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 87.991% |
| Cronos Group Inc. | -73.96 Million USD | 100.214% |
| OptiNose, Inc. | -35.48 Million USD | 100.445% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 100.016% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 100.374% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 99.339% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 96.804% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 102.517% |
| Radius Health, Inc. | -25.79 Million USD | 100.613% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 102.564% |
| ProPhase Labs, Inc. | -16.78 Million USD | 100.942% |
| Phibro Animal Health Corporation | 2.41 Million USD | 93.459% |
| Procaps Group S.A. | 42.54 Million USD | 99.629% |
| Alvotech | -551.73 Million USD | 100.029% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 101.538% |
| Viatris Inc. | 54.7 Million USD | 99.711% |
| Rockwell Medical, Inc. | -8.43 Million USD | 101.873% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 100.997% |
| SIGA Technologies, Inc. | 68.06 Million USD | 99.768% |
| Tilray Brands, Inc. | -244.98 Million USD | 100.065% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 98.684% |
| Shineco, Inc. | -22.44 Million USD | 100.704% |
| PetIQ, Inc. | 2.13 Million USD | 92.584% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 103.674% |
| Incannex Healthcare Limited | -18.45 Million USD | 100.856% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 99.937% |
| Alimera Sciences, Inc. | -20.13 Million USD | 100.785% |
| Silver Spike Investment Corp. | 7.34 Million USD | 97.847% |
| Assertio Holdings, Inc. | -331.94 Million USD | 100.048% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 102.397% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 101.936% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 100.883% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 100.788% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 100.099% |
| Hempacco Co., Inc. | -13.12 Million USD | 101.204% |
| Talphera, Inc. | -18.39 Million USD | 100.859% |
| Alvotech | -551.73 Million USD | 100.029% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 99.557% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 99.952% |
| Currenc Group, Inc. | -15.3 Million USD | 101.032% |
| Kamada Ltd. | 8.28 Million USD | 98.092% |
| Indivior PLC | 2 Million USD | 92.098% |
| Evoke Pharma, Inc. | -7.79 Million USD | 102.028% |
| Flora Growth Corp. | -57.03 Million USD | 100.277% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 100.788% |
| Evolus, Inc. | -61.68 Million USD | 100.256% |
| HUTCHMED (China) Limited | 100.78 Million USD | 99.843% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 99.885% |
| Akanda Corp. | -32.27 Million USD | 100.49% |